Skip to content

Clinical study on the treatment of sudden deafness with Acorus tatarinowii essential oil

Clinical study on the treatment of sudden deafness with Acorus tatarinowii essential oil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026001696
Enrollment
Unknown
Registered
2026-07-06
Start date
2025-06-06
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Sudden Sensorineural Hearing Loss

Interventions

unexposed:Standard Western Medicine Treatment Protocol
exposed:Standard Treatment with Acorus tatarinowii essential oil ear plug

Sponsors

Zhejiang Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Sudden sensorineural hearing loss occurring within 72 hours, with a hearing loss of =20 dBHL at least at two consecutive frequencies, mostly unilateral, with a few cases being bilateral either simultaneously or sequentially. 2) Age 18-70 years, no gender limitation. 3) Normal function of important organs such as liver and kidneys. 4) Informed consent and voluntary participants.

Exclusion criteria

Exclusion criteria: (1) Women who are pregnant or breastfeeding. (2) Exclude sudden deafness patients who cannot clearly state their medical history, have communication difficulties, or are unwilling to cooperate with examinations. (3) Apart from hearing loss, patients with no other accompanying symptoms or identifiable tongue and pulse signs, who do not meet the typical traditional Chinese medicine (TCM) pattern differentiation standards or whose syndromes are mixed or overlapping. (4) Exclude cases of sensorineural hearing loss with clear causes, such as Hunt syndrome, noise-induced hearing loss, traumatic hearing loss, toxic hearing loss, and sudden hearing loss caused by central lesions. (5) Exclude patients with structural ear diseases or pseudodeafness, as indicated by bilateral mastoid CT, internal auditory canal and cerebellopontine angle MRI, auditory brainstem response (ABR), tympanometry, and pure tone audiometry suggesting middle ear disease or acoustic neuroma. (6) Exclude sudden deafness patients with contraindications to tympanic cavity injection, corticosteroids, or batroxobin.

Design outcomes

Primary

MeasureTime frame
Pure tone audiometry;

Secondary

MeasureTime frame
Tinnitus Visual Analogue Scale;Self depression scale;Pittsburgh Sleep Quality Index;TCM Syndrome Efficacy Evaluation;

Countries

China

Contacts

Public ContactHe xiao

Zhejiang Chinese Medicine Hospital

roro2991@qq.com15868842240

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026